



Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey

Sang Hwa Lee · Wan Seop Kim
Yoo Duk Choi¹ · Jeong Wook Seo²
Joung Ho Han³ · Mi Jin Kim⁴
Lucia Kim⁵ · Geon Kook Lee⁶
Chang Hun Lee⁷ · Mee Hye Oh⁸
Gou Young Kim⁹ · Sun Hee Sung¹⁰
Kyo Young Lee¹¹ · Sun Hee Chang¹²
Mee Sook Rho¹³ · Han Kyeom Kim¹⁴
Soon Hee Jung¹⁵ · Se Jin Jang¹⁶
The Cardiopulmonary Pathology
Study Group of Korean Society of
Pathologists

Department of Pathology, Konkuk University School of Medicine, Seoul; ¹Chonnam National University Medical School, Gwangju; ²Seoul National University College of Medicine, Seoul; ³Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; ⁴Yeungnam University College of Medicine, Daegu; ⁵Inha University College of Medicine, Incheon; ⁶National Cancer Center, Goyang; ⁷Busan National University School of Medicine, Busan; ⁸Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan; ⁹Kyung Hee University School of Medicine, Seoul; ¹⁰Ewha Womans University School of Medicine, Seoul; ¹¹Seoul St. Mary's Hospital, Catholic University of Korea, Seoul; ¹²Inje University Ilsan Paik Hospital, Goyang; ¹³Dong-A University College of Medicine, Busan; ¹⁴Korea University College of Medicine, Seoul; ¹⁵Yonsei University Wonju College of Medicine, Wonju; ¹⁶Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Received: April 24, 2015

Revised: September 13, 2015

Accepted: September 14, 2015

Corresponding Author

Wan Seop Kim, MD, PhD
Department of Pathology, Konkuk University
Medical Center, Konkuk University School of
Medicine, 120-1 Neungdong-ro, Gwangjin-gu,
Seoul 05030, Korea
Tel: +82-2-2030-5642
Fax: +82-2-2030-5629
E-mail: wskim@kuh.ac.kr

Background: Analysis of mutations in the epidermal growth factor receptor gene (*EGFR*) is important for predicting response to *EGFR* tyrosine kinase inhibitors. The overall rate of *EGFR* mutations in Korean patients is variable. To obtain comprehensive data on the status of *EGFR* mutations in Korean patients with lung cancer, the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists initiated a nationwide survey. **Methods:** We obtained 1,753 reports on *EGFR* mutations in patients with lung cancer from 15 hospitals between January and December 2009. We compared *EGFR* mutations with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site, tumor cell dissection, and laboratory status. **Results:** The overall *EGFR* mutation rate was 34.3% in patients with non-small cell lung cancer (NSCLC) and 43.3% in patients with adenocarcinoma. *EGFR* mutation rate was significantly higher in women, never smokers, patients with adenocarcinoma, and patients who had undergone excisional biopsy. *EGFR* mutation rates did not differ with respect to patient age or procurement site among patients with NSCLC. **Conclusions:** *EGFR* mutation rates and statuses were similar to those in published data from other East Asian countries.

Key Words: Lung neoplasms; Receptor, epidermal growth factor; Mutation survey

Lung cancer is the leading cause of cancer-related death in Korea, accounting for approximately 20% of all cancer deaths.¹ Non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers, and the majority of patients with NSCLC present at an advanced cancer stage (stage III or IV).² In the last decade, several studies have been performed on the molecular stratification of NSCLC in order to provide targeted treatment based on activating or driver mutations in these tumors. Activating mutations in the epidermal growth factor receptor gene (*EGFR*) can be used as therapeutic targets for treatment of NSCLC. In the Iressa Pan-Asia Study, tumors with *EGFR* mutations showed a 71.2% clinical response to first-line treatment with gefitinib, while tumors with wild-type *EGFR* showed only a 1.1% response.³ Since then, several randomized control studies have shown an association between activating *EGFR* mutation and response to EGFR tyrosine kinase inhibitors (TKIs).⁴⁻⁹ Patient selection is important for using EGFR TKIs as the first-line treatment. At present, analysis of *EGFR* mutations is the accepted method for identifying patient response to EGFR TKIs. Direct DNA sequencing is a standard method for identifying mutations and is commonly used in the Asia-Pacific region.¹⁰ Any routinely available pathological specimen can be used for analyzing *EGFR* mutations, including formalin-fixed, paraffin-embedded tissues from surgical resections; small tissue biopsies; or cell block preparations.

Several publications have reported the prevalence of *EGFR* mutations in patients with NSCLC.¹⁰⁻¹⁴ The rates of *EGFR* mutations are higher in Asian countries than in Western countries. Further, rates of *EGFR* mutations in Korean patients range from 17.4% to 51.3%.^{10,15-22} Therefore, we performed a nationwide study of *EGFR* mutations in Korean patients with NSCLC in order to provide reliable information on the incidence and characteristics of *EGFR* mutations. This study was led by the Korean Cardiopulmonary Pathology Study Group.

MATERIALS AND METHODS

In all, 1,826 reports of *EGFR* mutation in patients with lung cancer were collected from 15 hospitals between January and December 2009 (Fig. 1). Of these, 24 reports of patients with small cell carcinoma and 49 reports of patients with malignancies from other than lung primary tumors were excluded from the study. Finally, 1,544 reports of primary tumor and 209 reports of metastatic tumor were included in the study. *EGFR* mutation status was compared with patient age, sex, history of smoking, histologic diagnosis, specimen type, procurement site,




Fig. 1. Geographical distribution of the 15 hospitals in Korea.

tumor cell dissection, and laboratory status. Smoker status was defined as having a greater than 10 pack-year history and currently smoking cigarettes every day or most days. An ex-smoker was someone who had smoked more than 100 cigarettes in their lifetime and who does not currently smoke. A light smoker was defined as a current smoker with a less than 10 pack-year history. A never-smoker was an adult who had never smoked a cigarette or who smoked fewer than 100 cigarettes in their lifetime.

Tumor specimens were divided into three types, namely, biopsy, cytology, and excision specimens. Biopsy specimens included small biopsy specimens obtained by performing bronchoscopic biopsy, transbronchial lung biopsy, percutaneous needle biopsy, pleural biopsy, or needle biopsy of metastatic sites. Cytology included cytologic specimens such as sputum, bronchial washing/brushing, pleural fluids, and aspiration biopsy cytology of primary or metastatic sites. Excision specimens included specimens obtained by performing excisional surgical biopsy such as segmentectomy, lobectomy, pneumonectomy, and metastasectomy. Procurement sites were divided into two types, namely, metastasis and primary sites. Tumor dissection indicated whether or not to perform microdissection of tumor cells. Laboratory status was classified into two types: in-house mutation testing, indicating that *EGFR* mutation analysis was performed in the hospital's laboratory facility, and out-sourced mutation testing, indicating that *EGFR* mutation analysis was not performed in the hospital's laboratory facility. All participants in the study were active members of the Korean Cardiopulmonary Pathology Study Group. This study was approved by the Institutional Review Board of Konkuk University Medical Center (No. KUH 1210011).

Statistical analysis

All statistical analyses were performed using SPSS ver. 18.0 (SPSS Inc., Chicago, IL, USA). Chi-square test and Fisher exact test were used to determine the correlations between *EGFR* mutation status and clinicopathological parameters. A p-value of < .05 was considered statistically significant.

RESULTS

Patient characteristics

The average age of 1,753 patients with NSCLC was 62.74 ± 11.31 years (range, 16 to 89 years); of these, 875 patients (49.9%) were aged ≥ 65 years. Of the 1,753 patients, 1,000 (57%) were men and 753 (43%) were women. Of the 1,753 patients, 555 (31.7%) were smokers, 39 (2.2%) were light smokers, 170 (9.7%) were ex-smokers, 849 (48.4%) were never-smokers, and 140 (8.0%) patients had an unknown smoking history. Of the specimens used for *EGFR* mutation testing, 114 (6.5%) were cytology specimens, 1,066 (60.8%) were biopsy specimens, and 573 (32.7%) were excision specimens (Fig. 2). With respect to procurement sites, specimens from 1,544 patients (88.1%) were procured from primary tumor sites, while those from 209 patients (11.9%) were procured from metastatic sites. In all, 1,012 patients (57.7%) underwent tumor microdissection, while the remaining 741 patients (42.3%) did not. The histological types of the tumor specimens were as follows: adenocarcinoma in 1,292 (73.7%), squamous cell carcinoma in 347 (19.8%), NSCLC type undetermined in 69 (3.9%), pleomorphic carcinoma in 13 (0.7%), large cell neuroendocrine cell carcinoma in 12 (0.7%), large cell carcinoma in nine (0.5%), sarcomatoid carcinoma in five (0.3%), carcinoid tumor in two (0.1%), mucoepidermoid carcinoma in two (0.1%), carcinosarcoma in one (0.05%), and lymphoepithelioma-like carcinoma in one (0.05%). Among the 1,753 *EGFR* tests, 1,299 (7 institutions, 74.1%) were performed within the same pathology laboratory, and 454 (8 insti-




Fig. 2. Specimen types used for *EGFR* mutation testing. *EGFR*, epidermal growth factor receptor.

tutions, 25.9%) were performed in outside laboratories. *EGFR* mutations in specimens obtained from 14 hospitals were identified by direct sequencing, while those in specimens obtained from the remaining hospital were identified by pyrosequencing. Characteristics of patients included in the study are summarized in Table 1.

Frequency of *EGFR* mutations

In all, 601 cases of *EGFR* mutation (34.3%) were detected in NSCLC. Of these 601 patients, 560 (43.3%) had adenocarcinoma, 30 (8.6%) had squamous cell carcinoma, eight (11.6%) had NSCLC type undetermined, two (15.4%) had pleomorphic carcinoma, and one (8.3%) had large cell neuroendocrine carcinoma.

Table 1. Characteristics of patients

Characteristic	No. (%)
Age, mean (range, yr)	62.7 (16–89)
< 65	878 (50.1)
≥ 65	875 (49.9)
Sex	
Female	753 (43)
Male	1,000 (57)
Smoking history	
Smoker	555 (31.7)
Light smoker	39 (2.2)
Ex-smoker	170 (9.7)
Never smoker	849 (48.4)
Unknown	140 (8.0)
Specimen type	
Cytology	114 (6.5)
Biopsy	1,066 (60.8)
Excision	573 (32.7)
Procurement site	
Primary	1,544 (88.1)
Metastasis	209 (11.9)
Tumor dissection	
No	741 (42.3)
Yes	1,012 (57.7)
Histologic type	
Adenocarcinoma	1,292 (73.7)
Squamous cell carcinoma	347 (19.8)
Non-small cell carcinoma	69 (3.9)
Pleomorphic carcinoma	13 (0.7)
Large cell neuroendocrine carcinoma	12 (0.7)
Large cell carcinoma	9 (0.5)
Sarcomatoid carcinoma	5 (0.3)
Carcinoid tumor	2 (0.1)
Mucoepidermoid carcinoma	2 (0.1)
Carcinosarcoma	1 (0.05)
Lymphoepithelioma-like carcinoma	1 (0.05)
Laboratory status	
Out-sourcing	454 (25.9)
In-house	1,299 (74.1)

ma. In all, 389 never-smokers with adenocarcinoma (52.4%) had *EGFR* mutations. Of the 601 patients with NSCLC who had *EGFR* mutations, 30 (5%), 313 (52.1%), 31 (5.2%), and 205 (34.1%) had mutations in exons 18, 19, 20, and 21, respectively; in addition, 22 patients (3.7%) had double mutations (Fig. 3). Further, 13 patients (2.2%) had T790M mutation; of these, four patients had only the T790M mutation.

Interestingly, specimens obtained from two in-house laboratories showed low *EGFR* mutation rates of 16.7% (2/12 specimens) and 9.3% (4/43 specimens) in patients with NSCLC, respectively, and 28.6% (2/7 specimens) and 11.5% (3/26 specimens) in patients with adenocarcinoma and never-smokers (Fig. 4). In brief, one laboratory that detected a 16.7% mutation rate in patients with NSCLC analyzed tumor specimens from 12 patients. Of these 12 patients, 10 had adenocarcinoma, one had large cell carcinoma, and one had NSCLC. Of the 10 patients with adenocarcinoma, seven, two, and one were never-smokers,




Fig. 3. Frequency of mutations according to exons: 601 mutations in 1,753 specimens from patients with non-small cell lung cancer.




Fig. 4. *EGFR* mutation rates in in-house laboratories. *EGFR*, epidermal growth factor receptor.

ex-smokers, and smoker, respectively. All the specimens were obtained by surgical excision and were analyzed by tumor microdissection. The laboratory that detected a 9.3% mutation rate in patients with NSCLC analyzed tumor specimens from 43 patients. Of these 43 patients, 41 had adenocarcinoma, one had NSCLC, and one had squamous cell carcinoma. Of the 41 patients with adenocarcinoma, 25, 6, and 10 were never-smokers, ex-smokers, and smokers, respectively. Of the 43 specimens analyzed in this laboratory, six were surgical excision specimens, 29 were biopsy specimens, and eight were cytology specimens. All 43 specimens were analyzed without tumor microdissection. A total of four *EGFR* mutations were found, and all of them were adenocarcinoma. They included three never-smokers and one ex-smoker. Moreover, of the four mutations, two were detected in excision specimens and two were detected in biopsy specimens.

A total of 125 *EGFR* mutations were detected in a total of 430 male patients with adenocarcinoma who had a smoking history.

Differences in *EGFR* mutation status

Differences in *EGFR* mutation status according to clinicopathological variables are summarized in Table 2. Among patients with NSCLC, female ($p < .001$), age < 65 years ($p = .007$), light or no smoking ($p < .001$), excision specimen ($p = .002$), and in-house *EGFR* mutation testing ($p < .001$) were correlated with significantly higher *EGFR* mutation rate. Among patients with adenocarcinoma, female ($p < .001$), light or no smoking ($p < .001$), excision specimen ($p < .001$), tumor microdissection ($p = .001$), and in-house *EGFR* mutation testing ($p = .046$) were correlated with significantly higher *EGFR* mutation rate. According to specimen status, the *EGFR* mutation rate was 48.1%, 47.2%, and 63.4% in cytology, biopsy, and excision specimen, respectively, from a total of 742 patients with adenocarcinoma and never-smoker status. According to laboratory status, the *EGFR* mutation rate in patients with NSCLC (38.2% vs 23.1%, $p < .001$) and adenocarcinoma (44.7% vs 37.6%, $p = .046$) was significantly higher in in-house tested specimens. Among patients with squamous cell carcinoma, female ($p = .001$) and light to no smoking ($p = .017$) were correlated with significantly higher *EGFR* mutation rate.

DISCUSSION

The present study identified the frequencies of *EGFR* mutations in Korean patients with NSCLC. The *EGFR* mutation rate was 34.3% and 43.3% among patients with NSCLC and adeno-

Table 2. EGFR mutation status according to the clinicopathological variables

Variable	NSCLC			Adenocarcinoma			SqCC		
	Negative	Positive	p-value	Negative	Positive	p-value	Negative	Positive	p-value
Sex			<.001			<.001			.001
Female	374 (49.7)	379 (50.3)		314 (46.5)	361 (53.5)		31 (75.6)	10 (24.4)	
Male	778 (77.8)	222 (22.2)		418 (67.7)	199 (32.3)		286 (93.5)	20 (6.5)	
Age (yr)			.007			.911			.565
< 65	551 (62.7)	328 (37.3)		399 (56.5)	307 (43.5)		100 (90.1)	11 (9.9)	
> 65	601 (68.8)	273 (31.2)		333 (56.8)	253 (43.2)		217 (91.9)	19 (8.1)	
Smoking			<.001			<.001			.017
Ex-smoker	143 (84.1)	27 (15.9)		88 (77.2)	26 (22.8)		48 (98)	1 (2)	
Light smoker	22 (56.4)	17 (43.6)		17 (53.1)	15 (46.9)		2 (66.7)	1 (33.3)	
Never smoker	442 (52.1)	407 (47.9)		353 (47.6)	389 (52.4)		58 (82.9)	12 (17.1)	
Smoker	446 (80.4)	109 (19.6)		227 (70.7)	94 (29.3)		168 (92.8)	13 (7.2)	
Unknown	99 (70.7)	41 (29.3)		47 (56.6)	36 (43.4)		41 (93.2)	3 (6.8)	
Specimen type			.002			<.001			.535
Biopsy	728 (68.3)	338 (31.7)		453 (59.8)	305 (40.2)		215 (90.7)	22 (9.3)	
Cytology	80 (70.2)	34 (29.8)		70 (67.3)	34 (32.6)				
Excision	344 (60)	229 (40)		209 (48.6)	221 (51.4)		102 (92.7)	8 (7.3)	
Procurement site			.797			.586			.38
Metastasis	139 (66.5)	70 (33.5)		95 (58.6)	67 (41.4)		17 (100)	0 (0)	
Primary	1,013 (65.6)	531 (34.4)		637 (56.4)	493 (43.6)		300 (90.9)	30 (9.1)	
Tumor dissection			.362			.001			.105
No	478 (64.5)	263 (35.5)		401 (61.3)	253 (38.7)		45 (84.9)	8 (15.1)	
Yes	674 (66.6)	338 (33.4)		331 (51.9)	307 (48.1)		272 (92.5)	22 (7.5)	
Laboratory status			<.001			.046			.238
In-house	803 (61.8)	496 (38.2)		581 (55.3)	469 (44.7)		144 (89.4)	17 (10.6)	
Out-sourcing	349 (76.9)	105 (23.1)		151 (62.4)	91 (37.6)		173 (93)	13 (7)	

Values are presented as number (%).

EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; SqCC, squamous cell carcinoma.

carcinoma, respectively, and 52.4% among never-smokers with adenocarcinoma. The frequencies were in the range of those previously reported in Korean studies, with 17.4%–40.8% in NSCLC, 21.5%–54.4% in adenocarcinoma, and 47%–64.9% in adenocarcinoma with never-smokers.^{10,15–21} The results of the present study were also in the range of those from other Asian countries (30%–61.1% in NSCLC and 44.1%–67.4% in adenocarcinoma) and showed a high mutation rate compared with those reported in Western countries (4.5%–13.3% in NSCLC and 16% in adenocarcinoma).^{3,11,12,23} Recently, a large retrospective database study was performed on EGFR mutation testing practices in the Asia-Pacific region.¹⁰ EGFR mutation rates among patients with NSCLC reported in the present study were very similar to those reported by Yatabe *et al.*¹⁰ (39.6% and 35.8% EGFR mutation rate among newly diagnosed patients with NSCLC) in the Asia-Pacific region and Korea, respectively, in 2011. The overall distribution pattern of EGFR mutations (i.e., high mutation rates in female patients, never-smokers, and patients with adenocarcinoma) was similar to that reported in previous studies.

The most frequent mutation was an exon 19 deletion, and the most frequent drug resistance-associated mutation was T790M. Chan *et al.*²⁴ identified EGFR mutation hot spots in exons 19 (48%) and 21 (41%) in 3,023 specimens. The highest incidence of mutations in EGFR was observed for L858R, del(E746-A750), and del(E749-T751), in that order. Shi *et al.*²⁵ reported 43% and 42.6% mutation rates in exons 19 and 21, respectively, among 1,450 specimens, with the most common drug resistance-associated mutation being S768I. The present study reported 52.1% and 34.1% mutation rates in exons 19 and 21, respectively. However, the sum of mutation rates in exons 19 and 21 was 86.2%, which was similar to that reported in studies performed in other countries.

Two laboratories in the present study detected low EGFR mutation rates. Commonalities between these two institutions included a period less than 1 year after starting the EGFR mutation analysis and use of the direct sequencing method. Well-equipped laboratories and technicians skilled at performing EGFR mutation analysis, active engagement of pathologists in molecular testing, and quality assurance were important for ob-

taining accurate results.

A high incidence of *EGFR* mutations (29.7%) has been reported in Korean male smokers with adenocarcinoma.²⁰ In the present study, *EGFR* mutation rate was 29.1% in male patients with adenocarcinoma who had a smoking history (125 out of 430 patients). This result supports the recommendation of a previous study that *EGFR* mutation tests should be performed in all patients with adenocarcinoma regardless of sex or smoking history.²⁰

Because minimally invasive diagnostic procedures are often used in the diagnostic workup of lung cancer, small tissue specimens and, more importantly, cytology specimens might be the only specimens available for *EGFR* mutation analysis. In the present study, a total of 73.3% of specimens were cytology or biopsy samples. However, these specimens showed a significantly low mutation rate compared to excision specimens in patients with NSCLC even in patients with adenocarcinoma and never-smokers. Although our results showed significantly higher mutation rates in surgically resected specimens, many studies have reported that small biopsy and cytology specimens are more suitable for performing mutation testing.²⁶⁻²⁹

A quick and accurate test for detecting *EGFR* mutations is very important for proper selection of patients for EGFR TKI therapy. This highlights the need for standard guidelines specific to medical conditions in Korea for *EGFR* mutation testing. Many methods are available for detecting *EGFR* mutations, and these methods have different advantages and disadvantages. However, there is no consensus on the best method for detecting *EGFR* mutations.³⁰ In Korea, most pathology laboratories use direct DNA sequencing, pyrosequencing, or the peptide nucleic acid (PNA) clamp method for detecting *EGFR* mutations in formalin-fixed, paraffin-embedded tissue specimens. In the present study, specimens obtained from 14 hospitals were analyzed using direct DNA sequencing, a classic method for detecting mutations. However, this technique is associated with low sensitivity and requires > 25% mutant DNA for analysis.³¹ Pyrosequencing is a more sensitive method that needs more than 1% to 20% mutant DNA for analysis.^{32,33} PNA clamping is a simple, rapid, and sensitive method that can detect mutations in as few as 1% mutant alleles in a mixture of mutant and wild-type DNA.³⁴ These three methods show a good concordance of 82%–87.5%.^{35,36} We recommend that the use of the available methods for *EGFR* mutation analysis in each institution and laboratory should be under strict quality control. The quality and quantity of DNA are important for avoiding false-negative results.²⁹ In the present study, tumor microdissection specimens from patients with adenocarcinoma showed higher

mutation rates than non-dissection specimens. We recommend that pathologists verify the adequacy of specimens and reanalyze *EGFR* mutations to prevent false-negative results.

According to laboratory status, the *EGFR* mutation rate in patients with NSCLC (38.2% vs 23.1%, $p < .001$) and adenocarcinoma (44.7% vs 37.6%, $p = .046$) was significantly higher in the in-house test in the present study. However, the proportion of never-smoker patients with adenocarcinoma was 48.3% (628 out of 1,299 patients) in the in-house test and 25.1% (114 out of 454 patients) in the out-sourced test. Moreover, *EGFR* mutation rate in never-smokers with adenocarcinoma was 52.7% based on in-house mutation testing and 50.9% based on out-sourced mutation testing. These results indicate significant differences between in-house and out-sourced mutation testing, which might be because of a bias in patient selection.

In the future, we will aim to develop recommendations for more standardized application and interpretation of results of *EGFR* mutation tests in patients with NSCLC. These recommendations will discuss patients, turnaround time, specimen type, minimum specimen size, specimen collection and storage, tumor cell content, methodology such as DNA extraction, and reporting form. In addition, we aim to design a QA program for use during *EGFR* mutation analysis.

The present study had limitations. Pathological diagnosis of patients included in the study was not confirmed. In addition, immunohistochemical staining to classify the histologic type of NSCLC was not performed for all patient samples. Further, our data were collected from hospitals where diagnosis was performed by pulmonary pathologists. Therefore, our results might represent the current status of NSCLC subtypes in Korea.

In conclusion, *EGFR* mutation rate showed significant differences with respect to sex, smoking history, histologic diagnosis, specimen type, tumor cell dissection, and institution. However, it did not show differences with respect to age, procurement site, or laboratory status. The relative frequency of *EGFR* mutations in Korea was not similar to those reported in other Asian countries.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

We would like to sincerely thank Seo-Young Oh, MS; Noh-Young Lee, MS; and Yoo-Min Hong, MRA for their devoted efforts toward data set mining and cleaning.

REFERENCES

1. Jung KW, Won YJ, Kong HJ, *et al.* Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. *Cancer Res Treat* 2015; 47: 127-41.
2. Owonikoko TK, Ragin CC, Belani CP, *et al.* Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database. *J Clin Oncol* 2007; 25: 5570-7.
3. Mok TS, Wu YL, Thongprasert S, *et al.* Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009; 361: 947-57.
4. Rosell R, Carcereny E, Gervais R, *et al.* Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced *EGFR* mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2012; 13: 239-46.
5. Zhou C, Wu YL, Chen G, *et al.* Erlotinib versus chemotherapy as first-line treatment for patients with advanced *EGFR* mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. *Lancet Oncol* 2011; 12: 735-42.
6. Maemondo M, Inoue A, Kobayashi K, *et al.* Gefitinib or chemotherapy for non-small-cell lung cancer with mutated *EGFR*. *N Engl J Med* 2010; 362: 2380-8.
7. Mitsudomi T, Morita S, Yatabe Y, *et al.* Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJ-TOG3405): an open label, randomised phase 3 trial. *Lancet Oncol* 2010; 11: 121-8.
8. Fukuoka M, Wu YL, Thongprasert S, *et al.* Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). *J Clin Oncol* 2011; 29: 2866-74.
9. Yang JC, Wu YL, Schuler M, *et al.* Afatinib versus cisplatin-based chemotherapy for *EGFR* mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. *Lancet Oncol* 2015; 16: 141-51.
10. Yatabe Y, Kerr KM, Utomo A, *et al.* *EGFR* mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. *J Thorac Oncol* 2015; 10: 438-45.
11. Yang CH. *EGFR* tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future. *Lung Cancer* 2008; 60 Suppl 2: S23-30.
12. Shigematsu H, Lin L, Takahashi T, *et al.* Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. *J Natl Cancer Inst* 2005; 97: 339-46.
13. Skov BG, Høgdall E, Clementsen P, *et al.* The prevalence of *EGFR* mutations in non-small cell lung cancer in an unselected Caucasian population. *APMIS* 2015; 123: 108-15.
14. Gahr S, Stoehr R, Geissinger E, *et al.* *EGFR* mutational status in a large series of Caucasian European NSCLC patients: data from daily practice. *Br J Cancer* 2013; 109: 1821-8.
15. Soung YH, Lee JW, Kim SY, *et al.* Mutational analysis of *EGFR* and *K-RAS* genes in lung adenocarcinomas. *Virchows Arch* 2005; 446: 483-8.
16. Bae NC, Chae MH, Lee MH, *et al.* *EGFR*, *ERBB2*, and *KRAS* mutations in Korean non-small cell lung cancer patients. *Cancer Genet Cytogenet* 2007; 173: 107-13.
17. Park S, Holmes-Tisch AJ, Cho EY, *et al.* Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. *J Thorac Oncol* 2009; 4: 809-15.
18. Lee YJ, Park IK, Park MS, *et al.* Activating mutations within the *EGFR* kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma. *J Cancer Res Clin Oncol* 2009; 135: 1647-54.
19. Ahn MJ, Park BB, Ahn JS, *et al.* Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? *Clin Cancer Res* 2008; 14: 3860-6.
20. Sun PL, Seol H, Lee HJ, *et al.* High incidence of *EGFR* mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, *EGFR*/*TTF-1* expressions, and clinical features. *J Thorac Oncol* 2012; 7: 323-30.
21. Kim YT, Seong YW, Jung YJ, *et al.* The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. *J Thorac Oncol* 2013; 8: 171-8.
22. Choi YL, Sun JM, Cho J, *et al.* *EGFR* mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital. *PLoS One* 2013; 8: e56011.
23. Ma BB, Hui EP, Mok TS. Population-based differences in treatment outcome following anticancer drug therapies. *Lancet Oncol* 2010; 11: 75-84.
24. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer: search and destroy. *Eur J Cancer* 2006; 42: 17-23.
25. Shi Y, Au JS, Thongprasert S, *et al.* A prospective, molecular epidemiology study of *EGFR* mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIO-

- NEER). *J Thorac Oncol* 2014; 9: 154-62.
26. Liu J, Zhao R, Zhang J, Zhang J. ARMS for *EGFR* mutation analysis of cytologic and corresponding lung adenocarcinoma histologic specimens. *J Cancer Res Clin Oncol* 2015; 141: 221-7.
 27. Heymann JJ, Bulman WA, Maxfield RA, *et al.* Molecular testing guidelines for lung adenocarcinoma: utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples. *Cytojournal* 2014; 11: 12.
 28. Khode R, Larsen DA, Culbreath BC, *et al.* Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. *Cancer Cytopathol* 2013; 121: 361-9.
 29. Sun PL, Jin Y, Kim H, Lee CT, Jheon S, Chung JH. High concordance of *EGFR* mutation status between histologic and corresponding cytologic specimens of lung adenocarcinomas. *Cancer Cytopathol* 2013; 121: 311-9.
 30. Pirker R, Herth FJ, Kerr KM, *et al.* Consensus for *EGFR* mutation testing in non-small cell lung cancer: results from a European workshop. *J Thorac Oncol* 2010; 5: 1706-13.
 31. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. *Clin Cancer Res* 2007; 13: 4954-5.
 32. Kim SK, Kim DL, Han HS, *et al.* Pyrosequencing analysis for detection of a *BRAFV600E* mutation in an FNAB specimen of thyroid nodules. *Diagn Mol Pathol* 2008; 17: 118-25.
 33. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. Pyrosequencing, a method approved to detect the two major *EGFR* mutations for anti *EGFR* therapy in NSCLC. *J Exp Clin Cancer Res* 2011; 30: 57.
 34. Choi JJ, Cho M, Oh M, Kim H, Kil MS, Park H. PNA-mediated real-time PCR clamping for detection of *EGFR* mutations. *Bull Korean Chem Soc* 2010; 31: 3525-9.
 35. Lee HJ, Xu X, Kim H, *et al.* Comparison of direct sequencing, PNA clamping-real time polymerase chain reaction, and pyrosequencing methods for the detection of *EGFR* mutations in non-small cell lung carcinoma and the correlation with clinical responses to *EGFR* tyrosine kinase inhibitor treatment. *Korean J Pathol* 2013; 47: 52-60.
 36. Kim HJ, Lee KY, Kim YC, *et al.* Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. *Lung Cancer* 2012; 75: 321-5.